Merit Medical Systems (MMSI) EBITDA Margin (2010 - 2026)

Merit Medical Systems has disclosed EBITDA Margin across 17 years of filings, most recently posting 11.56% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 11.56%, up 2.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 2.53% (down 11.0% YoY), and the FY2025 annual result was 2.37%, up 5.0% from the prior year.
• EBITDA Margin came in at 11.56% for Q1 2026 at Merit Medical Systems, up from 24.02% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 13.59% in Q2 2024 to a low of 24.67% in Q4 2024.
• The 5-year median for EBITDA Margin is 10.37% (2022), against an average of 4.24%.
• Across the five-year window, EBITDA Margin surged 471 bps in 2022 and sank 3095 bps in 2023, its largest moves.
• Merit Medical Systems' EBITDA Margin stood at 10.37% in 2022, then tumbled by 299 bps to 20.58% in 2023, then slipped by 20 bps to 24.67% in 2024, then climbed by 3 bps to 24.02% in 2025, then jumped by 148 bps to 11.56% in 2026.
• The last three EBITDA Margin figures came in at 11.56% (Q1 2026), 24.02% (Q4 2025), and 11.09% (Q3 2025), per Business Quant data.